ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide a Corporate Strategic Update

Rhea-AI Summary

ThermoGenesis Holdings, Inc. (Nasdaq: THMO) will release its first quarter financial results for the period ending March 31, 2022, alongside a corporate strategic update on May 19, 2022, after trading hours. A conference call will follow at 1:30 p.m. PT/4:30 p.m. ET. The company specializes in automated cell processing tools and services, particularly in the cell and gene therapy markets. The event will be accessible via telephone and webcast, with a replay available on their website for three months.

Positive

• Company is scheduled to announce financial results, indicating ongoing operations.
• Focus on automated technologies for CAR-T and cell-based therapies, indicating growth potential.

Negative

• None.

Conference Call to be Held on May 19, 2022

RANCHO CORDOVA, Calif., May 18, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 and provide a corporate strategic update on Thursday, May 19, 2022, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET.

To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts/.

A webcast replay will be available on ThermoGenesis' website for three months by visiting the Investor page of the Company's website at www.thermogenesis.com.

About ThermoGenesis Holdings, Inc.

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.

Company Contact: 
Wendy Samford
916-858-5191
ir@ThermoGenesis.com

Investor Contact: 
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com

 

View original content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-announce-financial-results-for-the-first-quarter-ended-march-31-2022-and-provide-a-corporate-strategic-update-301549870.html

SOURCE ThermoGenesis Holdings, Inc.

FAQ

What date will ThermoGenesis Holdings announce its financial results?

ThermoGenesis Holdings will announce its financial results on May 19, 2022.

What is the significance of the May 19, 2022 conference call for THMO?

The conference call will provide insights into the financial performance and strategic direction of ThermoGenesis Holdings.

How can I access the May 19 conference call for ThermoGenesis Holdings?

You can participate by dialing the specified numbers or accessing the live webcast through their official website.

What are the key focuses of ThermoGenesis Holdings in their business operations?

The company focuses on automated technologies for CAR-T and other cell-based therapies.